Patrick C N Rensen Selected Research

Hypertriglyceridemia

7/2022	Comprehensive (apo)lipoprotein profiling in patients with genetic hypertriglyceridemia using LC-MS and NMR spectroscopy.
1/2021	Impaired Very-Low-Density Lipoprotein catabolism links hypoglycemia to hypertriglyceridemia in Glycogen Storage Disease type Ia.
1/2020	Disruption of Phospholipid Transfer Protein-Mediated High-Density Lipoprotein Maturation Reduces Scavenger Receptor BI Deficiency-Driven Atherosclerosis Susceptibility Despite Unexpected Metabolic Complications.
11/2015	Cold Exposure Partially Corrects Disturbances in Lipid Metabolism in a Male Mouse Model of Glucocorticoid Excess.
8/2013	Apolipoprotein A5 deficiency aggravates high-fat diet-induced obesity due to impaired central regulation of food intake.
12/2011	Aspirin reduces hypertriglyceridemia by lowering VLDL-triglyceride production in mice fed a high-fat diet.
5/2011	Hepatocyte-specific IKK-β activation enhances VLDL-triglyceride production in APOE*3-Leiden mice.
6/2010	Ritonavir protects against the development of atherosclerosis in APOE*3-Leiden mice.
5/2009	Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein.
5/2008	ApoE2-associated hypertriglyceridemia is ameliorated by increased levels of apoA-V but unaffected by apoC-III deficiency.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Patrick C N Rensen Research Topics

Disease

57	Atherosclerosis 01/2022 - 01/2006
41	Obesity 01/2022 - 06/2007
25	Type 2 Diabetes Mellitus (MODY) 04/2022 - 05/2005
24	Inflammation (Inflammations) 04/2022 - 08/2006
19	Body Weight (Weight, Body) 01/2022 - 04/2012
19	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 06/2006
17	Hypertriglyceridemia 07/2022 - 07/2004
15	Insulin Resistance 11/2022 - 05/2005
15	Dyslipidemias (Dyslipidemia) 01/2021 - 05/2009
10	Hyperlipidemias (Hyperlipidemia) 04/2022 - 02/2005
9	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022 - 06/2004
8	Sepsis (Septicemia) 10/2021 - 01/2005
7	Fatty Liver 01/2022 - 08/2006
7	Glucose Intolerance 01/2019 - 01/2012
5	Atherosclerotic Plaque (Atheroma) 01/2022 - 01/2013
5	Overweight 01/2021 - 10/2017
5	Weight Gain 01/2021 - 05/2015
5	Infections 01/2021 - 02/2008
5	Hypercholesterolemia 12/2017 - 01/2006
4	Coronary Artery Disease (Coronary Atherosclerosis) 01/2022 - 01/2016
4	Metabolic Diseases (Metabolic Disease) 01/2021 - 01/2018
3	Burns 01/2022 - 11/2015
3	Septic Shock (Toxic Shock Syndrome) 01/2021 - 08/2017
3	Weight Loss (Weight Reduction) 12/2020 - 12/2014
3	Alzheimer Disease (Alzheimer's Disease) 01/2019 - 04/2008
3	Chronic Obstructive Pulmonary Disease (COPD) 01/2017 - 01/2013
2	Cushing Syndrome 10/2021 - 10/2013
2	Coronary Disease (Coronary Heart Disease) 01/2021 - 11/2011
2	Fibrosis (Cirrhosis) 11/2020 - 01/2020
2	Endotoxemia 01/2020 - 08/2008
2	Prediabetic State (Prediabetes) 01/2019 - 11/2018
2	Non-alcoholic Fatty Liver Disease 12/2018 - 01/2018
2	Emphysema 01/2017 - 01/2013
2	Thyroid Neoplasms (Thyroid Cancer) 01/2014 - 05/2009

Drug/Important Bio-Agent (IBA)

41	Apolipoproteins E (ApoE)IBA 01/2022 - 02/2005
37	Triglycerides (Triacylglycerol)IBA 01/2022 - 06/2004
34	LipidsIBA 01/2022 - 05/2005
32	CholesterolIBA 01/2022 - 01/2005
24	Lipoproteins (Lipoprotein)IBA 07/2022 - 07/2004
24	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 05/2005
17	ApolipoproteinsIBA 01/2020 - 01/2005
15	Insulin (Novolin)FDA Link 11/2022 - 12/2011
14	Fatty Acids (Saturated Fatty Acids)IBA 11/2022 - 06/2004
14	Cholesterol Ester Transfer ProteinsIBA 10/2021 - 11/2006
13	HDL CholesterolIBA 01/2022 - 05/2008
11	Lipoprotein Lipase (Diacylglycerol Lipase)IBA 07/2022 - 07/2004
11	oxidized low density lipoproteinIBA 01/2022 - 01/2005
10	HDL LipoproteinsIBA 01/2021 - 10/2006
7	LDL Receptors (LDL Receptor)IBA 12/2021 - 03/2007
7	Apolipoprotein C-I (Apolipoprotein C1)IBA 01/2011 - 02/2005
6	GlucocorticoidsIBA 10/2021 - 01/2013
6	CorticosteroneIBA 10/2021 - 08/2012
5	anacetrapibIBA 01/2021 - 01/2015
5	VLDL LipoproteinsIBA 01/2021 - 02/2006
5	EndocannabinoidsIBA 01/2021 - 01/2017
5	Liraglutide FDA Link 12/2020 - 01/2019
5	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2020 - 01/2012
5	LipopolysaccharidesIBA 01/2020 - 10/2006
5	Atorvastatin (Lipitor)FDA Link 12/2017 - 05/2006
5	Apolipoprotein C-IIIIBA 01/2016 - 07/2005
5	Apolipoproteins C (ApoC)IBA 01/2011 - 02/2005
4	Messenger RNA (mRNA)IBA 11/2022 - 01/2011
4	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 01/2021 - 01/2016
4	Scavenger Receptors (Scavenger Receptor)IBA 01/2021 - 01/2006
4	LDL CholesterolIBA 01/2021 - 06/2010
4	very low density lipoprotein triglycerideIBA 10/2017 - 07/2005
3	Proteins (Proteins, Gene)FDA Link 11/2022 - 09/2011
3	Apolipoprotein A-VIBA 01/2022 - 10/2006
3	Nonesterified Fatty Acids (NEFA)IBA 01/2021 - 02/2013
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2018 - 08/2013
3	CytokinesIBA 08/2017 - 08/2008
3	Niacin (Nicotinic Acid)FDA LinkGeneric 04/2014 - 09/2012
3	Angiopoietin-Like Protein 4IBA 01/2014 - 02/2013
3	Apolipoprotein E4IBA 11/2011 - 04/2008
2	Butyrates (Butyrate)IBA 11/2022 - 01/2018
2	Type 4 Melanocortin Receptor (Melanocortin-4 Receptor)IBA 03/2021 - 10/2014
2	alirocumabIBA 01/2021 - 01/2020
2	disodium (R,R)- 5- (2- ((2- (3- chlorophenyl)- 2- hydroxyethyl)- amino)propyl)- 1,3- benzodioxole- 2,3- dicarboxylateIBA 01/2021 - 02/2019
2	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2021 - 01/2019
2	Therapeutic UsesIBA 01/2021 - 11/2010
2	LDL Lipoproteins (beta Lipoproteins)IBA 01/2021 - 02/2019
2	Phospholipids (Phosphatides)FDA LinkGeneric 01/2021 - 11/2020
2	Proprotein Convertase 9IBA 01/2021 - 01/2016
2	Vasopressins (Vasopressin)IBA 01/2021 - 01/2019
2	CannabinoidsIBA 01/2021 - 12/2014
2	VLDL CholesterolIBA 01/2021 - 09/2009
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2021 - 02/2013
2	Phospholipid Transfer ProteinsIBA 01/2020 - 05/2006
2	Protein Isoforms (Isoforms)IBA 01/2019 - 06/2006
2	Hormones (Hormone)IBA 12/2018 - 01/2017
2	EnzymesIBA 01/2018 - 05/2010
2	Mifepristone (RU 486)FDA Link 01/2018 - 01/2016
2	SalicylatesIBA 12/2017 - 11/2010
2	SmokeIBA 01/2017 - 01/2013
2	IDL Lipoproteins (Lipoprotein, IDL)IBA 01/2016 - 07/2005
2	Metformin (Glucophage)FDA LinkGeneric 03/2014 - 07/2010
2	Apolipoprotein E3IBA 07/2013 - 05/2009
2	Biological ProductsIBA 02/2013 - 11/2011

Therapy/Procedure

7	Therapeutics 10/2021 - 01/2006
2	Caloric Restriction 01/2018 - 12/2011